| Entry |
|
|---|
| Name |
|
|---|
| Formula |
C12H15ClO3
|
|---|
| Exact mass |
242.071
|
|---|
| Mol weight |
242.6987
|
|---|
| Structure |
|
|---|
| Remark |
|
|---|
| Pathway |
| map05207 | Chemical carcinogenesis - receptor activation |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C10 LIPID MODIFYING AGENTS
C10A LIPID MODIFYING AGENTS, PLAIN
C10AB Fibrates
C10AB01 Clofibrate
D00279 Clofibrate (JP18/USP/INN) <JP>
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
21 Cardiovascular agents
218 Hyperlipidemia agents
2183 Clofibrates
D00279 Clofibrate (JP18/USP/INN)
Drug groups [BR:br08330]
Hypolipidemic agent
DG01946 Hypolipidemic agent
DG01733 PPAR alpha agonist
DG01547 Fibrate
DG00358 Clofibrate
D00279 Clofibrate
Drug classes [BR:br08332]
Cardiovascular agent
DG01946 Hypolipidemic agent
D00279 Clofibrate
Target-based classification of drugs [BR:br08310]
Nuclear receptors
Thyroid hormone like receptors
Peroxisome proliferator-activated receptor (PPAR)
NR1C1 (PPARA)
D00279 Clofibrate (JP18/USP/INN) <JP>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00279 Clofibrate
D00279 Clofibrate capsules
|
|---|
| Other DBs |
|
|---|
| KCF data |
ATOM 16
1 C8y C 22.6146 -14.4198
2 O2a O 23.8751 -13.7194
3 C1d C 25.0656 -14.4198
4 C7a C 26.2561 -13.7194
5 O7a O 27.5167 -14.4198
6 O6a O 26.2561 -12.3189
7 C1b C 28.7072 -13.7194
8 C1a C 29.8977 -14.4198
9 C8x C 21.4240 -13.7194
10 C8x C 20.1635 -14.4198
11 C8y C 20.1635 -15.8204
12 C8x C 21.3539 -16.5207
13 C8x C 22.6146 -15.8204
14 X Cl 18.9730 -16.4507
15 C1a C 24.0771 -15.4082
16 C1a C 26.0540 -15.4082
BOND 16
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 4 6 2
6 5 7 1
7 7 8 1
8 1 9 2
9 9 10 1
10 10 11 2
11 11 12 1
12 12 13 2
13 1 13 1
14 11 14 1
15 3 15 1
16 3 16 1
|
|---|
